Contact
Biography
Dr. Joseph Dib obtained his B.A in Clinical Psychology from Notre Dame University in 2013. Additionally, he obtained an MSc in General Psychology from Kingston University London in 2015. He completed his PhD in Psychiatry (Research) with an emphasis on Clinical Trials from the University of Nottingham under the supervision of Professor Clive Adams in 2020 before being appointed as Clinical Trial Manager for the TICH-3 Stroke Trial at the Queen's Medical Centre Nottingham June 2021. Subsequently, Dr. Dib spent one year working as a research psychologist and research associate at St. George's University Beirut in 2015 and as a clinical trial manager at the Psychiatric Hospital of the Cross Beirut from 2016-2019 while undertaking his doctorate.
Expertise Summary
Main interests in expertise pertaining to clinical trials include pre-trial set up, management of trials including ethical approvals, monitoring, site close down, contract reviews and negotiations. Although Joseph specialised mainly in psychiatry and mental health, he is very interested in clinical trial research in all domains.
Research Summary
Dr. Dib's interest lies in evidence based medicine and he specialises in clinical trials specifically in the emergency setting, conducting surveys of research sites to ensure appropriate conditions… read more
Current Research
Dr. Dib's interest lies in evidence based medicine and he specialises in clinical trials specifically in the emergency setting, conducting surveys of research sites to ensure appropriate conditions and a strong knowledge in clinical bio-ethics pertaining to clinical trials. He is currently clinical trial manager overseeing the TICH-3 Stroke Trial specifically in charge of setting up sites internationally where TICH-3 will be taking place.
Past Research
Dr. Dib's thesis centred around rapid tranquilisation in the psychiatric emergency setting. No one anywhere knows what type of intervention works best concerning rapid tranquilisation and research in this domain is still limited. Additionally, surveys conducted on opinion to what works best differs strongly to what happens in real world practice. His randomised clinical trial, 'TREC-Lebanon', was the first emergency psychiatric trial to be conducted in the MENA region. It involved randomising a total of 100 patients presenting with aggression to the psychiatric emergency setting to either haloperidol plus promethazine or haloperidol plus promethazine plus chlorpromazine in which the latter intervention was unique only to Lebanon and has never been randomised in a clinical trial before. The results highlighted that the additional inclusion of chlorpromazine does not necessary assist in quicker tranquilisation but could potentially be problematic with added adverse effects thus the well tested haloperidol plus promethazine is a safer choice when presented with the option. The results of the trial has impacted national policy as well as saved a fortune in reducing costs of adding the additional drug but most importantly, patients who are given the double therapy are at a reduced risk of developing adverse effects.